Tocilizumab
- PDF / 169,913 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 55 Downloads / 168 Views
1 S
Lobar pneumonia following off label use: case report A 52-year-old man developed lobar pneumonia following off label treatment with tocilizumab for COVID-19. The man, who had a history of diabetes, admitted to the hospital with fever, shortness of breath, sweating and cough. His diabetes was controlled with metformin. Subsequently, he was diagnosed with COVID-19 and received off label treatment with chloroquine, oseltamivir [Tamiflu], lopinavir/ritonavir [Kaletra], vancomycin, ribavirin and levofloxacin. He also received oxygen and other symptomatic therapies. Despite the treatments, he developed respiratory distress on day 12 of the admission and his oxygen level was 60%. Hence, he was shifted to the ICU, where non-invasive ventilation was provided with positive end-expiratory pressure. One day after the invasive ventilation, his oxygen saturation level was in the range of 65–80%. Therefore, off label treatment with injection of tocilizumab 400mg vial [Actemra; route not stated] was given and his oxygen saturation level increased to 90%. Eventually, his COVID-19 had recovered. However, he had increase in the endotracheal tube secretion that became purulent on day 8 after tocilizumab administration. His lab test showed leukocytosis. His x-ray and CT scan of the chest showed lobar pneumonia and it was considered that the lobar pneumonia was secondary to tocilizumab. The man was treated with colchicine. But, his sputum examination showed acinetobacter sensitive to colchicine. His subsequent treatment and non-invasive adjuvant ventilation led to resolution of the lobar pneumonia and he was discharged with oxygen saturation level more than 92%. No shortness of breath or respiratory distress were noted at the time of discharge. Maleh PA, et al. The role of tocilizumab in treatment of a patient with COVID-19: A case report. Journal of Cellular and Molecular Anesthesia 5: 117-121, No. 2, Apr 2020. 803517996 Available from: URL: http://doi.org/10.22037/jcma.v5i2.30262
0114-9954/20/1832-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 28 Nov 2020 No. 1832
Data Loading...
